Universal thromboprophylaxis in ovarian cancer patients before and after surgery?

Gynecol Oncol. 2023 Sep:176:A1-A2. doi: 10.1016/j.ygyno.2023.08.003.

Authors

Sara Moufarrij¹, Laura Havrilesky², Elizabeth L Jewell³

Affiliations

¹ Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Duke University, Durham, NC, USA.
³ Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA. Electronic address: Jewelle@mskcc.org.

PMID: 37652618
DOI: 10.1016/j.ygyno.2023.08.003

No abstract available

Publication types

Editorial

MeSH terms

Anticoagulants / therapeutic use
Female
Humans
Ovarian Neoplasms* / surgery
Venous Thromboembolism* / etiology
Venous Thromboembolism* / prevention & control

Substances

Anticoagulants